ALK is an inclusion criterion in 78 clinical trials for non-small cell lung carcinoma, of which 54 are open and 24 are closed. Of the trials that contain ALK status and non-small cell lung carcinoma as inclusion criteria, 2 are early phase 1 (1 open), 20 are phase 1 (14 open), 11 are phase 1/phase 2 (8 open), 28 are phase 2 (18 open), 1 is phase 2/phase 3 (1 open), 11 are phase 3 (10 open), 2 are phase 4 (2 open), and 3 are no phase specified (0 open) [4].

Ceritinib, crizotinib, alectinib, brigatinib, lorlatinib, and pembrolizumab have evidence of efficacy in patients with ALK mutation in non-small cell lung carcinoma [4].

ALK is an inclusion criterion in 14 clinical trials for anaplastic large cell lymphoma, of which 7 are open and 7 are closed. Of the trials that contain ALK status and anaplastic large cell lymphoma as inclusion criteria, 1 is phase 1 (0 open), 6 are phase 1/phase 2 (3 open), and 7 are phase 2 (4 open) [4].

Crizotinib has evidence of efficacy in patients with ALK mutation in anaplastic large cell lymphoma [4].

Brigatinib, ceritinib, and crizotinib have evidence of efficacy in patients with ALK mutation in inflammatory myofibroblastic tumor [4].

ALK is an inclusion criterion in 30 clinical trials for malignant solid tumor, of which 23 are open and 7 are closed. Of the trials that contain ALK status and malignant solid tumor as inclusion criteria, 10 are phase 1 (6 open), 8 are phase 1/phase 2 (5 open), and 12 are phase 2 (12 open) [4].

ALK is an inclusion criterion in 12 clinical trials for diffuse large B-cell lymphoma, of which 11 are open and 1 is closed. Of the trials that contain ALK status and diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 5 are phase 2 (4 open), and 3 are phase 3 (3 open) [4].

ALK is an inclusion criterion in 9 clinical trials for ALK-positive large B-cell lymphoma, of which 9 are open and 0 are closed. Of the trials that contain ALK status and ALK-positive large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 2 are phase 3 (2 open) [4].

ALK is an inclusion criterion in 8 clinical trials for T-cell/histiocyte-rich large B-cell lymphoma, of which 8 are open and 0 are closed. Of the trials that contain ALK status and T-cell/histiocyte-rich large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 2 (3 open), and 3 are phase 3 (3 open) [4].

ALK is an inclusion criterion in 7 clinical trials for diffuse large B-cell lymphoma, not otherwise specified, of which 7 are open and 0 are closed. Of the trials that contain ALK status and diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 2 (2 open), and 3 are phase 3 (3 open) [4].

ALK is an inclusion criterion in 7 clinical trials for high grade B-cell lymphoma, not otherwise specified, of which 7 are open and 0 are closed. Of the trials that contain ALK status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [4].

ALK is an inclusion criterion in 6 clinical trials for EBV-positive diffuse large B-cell lymphoma, not otherwise specified, of which 6 are open and 0 are closed. Of the trials that contain ALK status and EBV-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].

ALK is an inclusion criterion in 6 clinical trials for melanoma, of which 5 are open and 1 is closed. Of the trials that contain ALK status and melanoma as inclusion criteria, 1 is phase 1 (1 open) and 5 are phase 2 (4 open) [4].

ALK is an inclusion criterion in 6 clinical trials for transformed non-hodgkin lymphoma, of which 6 are open and 0 are closed. Of the trials that contain ALK status and transformed non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [4].

ALK is an inclusion criterion in 5 clinical trials for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 5 are open and 0 are closed. Of the trials that contain ALK status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].

ALK is an inclusion criterion in 5 clinical trials for cancer, of which 2 are open and 3 are closed. Of the trials that contain ALK status and cancer as inclusion criteria, 3 are phase 1 (2 open) and 2 are phase 2 (0 open) [4].

ALK is an inclusion criterion in 5 clinical trials for double-hit lymphoma, of which 5 are open and 0 are closed. Of the trials that contain ALK status and double-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [4].

ALK is an inclusion criterion in 5 clinical trials for grade 3b follicular lymphoma, of which 5 are open and 0 are closed. Of the trials that contain ALK status and grade 3b follicular lymphoma as inclusion criteria, 2 are phase 1/phase 2 (2 open), 1 is phase 2 (1 open), and 2 are phase 3 (2 open) [4].

ALK is an inclusion criterion in 5 clinical trials for primary cutaneous diffuse large B-cell lymphoma, leg type, of which 5 are open and 0 are closed. Of the trials that contain ALK status and primary cutaneous diffuse large B-cell lymphoma, leg type as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [4].

ALK is an inclusion criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain ALK status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [4].

ALK is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ALK status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ALK status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (2 open) [4].

ALK is an inclusion criterion in 4 clinical trials for diffuse large B-cell lymphoma associated with chronic inflammation, of which 4 are open and 0 are closed. Of the trials that contain ALK status and diffuse large B-cell lymphoma associated with chronic inflammation as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].

ALK is an inclusion criterion in 4 clinical trials for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 4 are open and 0 are closed. Of the trials that contain ALK status and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 2 are phase 2 (2 open) and 2 are phase 3 (2 open) [4].

ALK is an inclusion criterion in 4 clinical trials for intravascular large B-cell lymphoma, of which 4 are open and 0 are closed. Of the trials that contain ALK status and intravascular large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].

ALK is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain ALK status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [4].

ALK is an inclusion criterion in 4 clinical trials for triple-hit lymphoma, of which 4 are open and 0 are closed. Of the trials that contain ALK status and triple-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [4].

ALK is an inclusion criterion in 3 clinical trials for anaplastic large cell lymphoma, ALK-positive, of which 2 are open and 1 is closed. Of the trials that contain ALK status and anaplastic large cell lymphoma, ALK-positive as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (1 open) [4].

ALK is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ALK status and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

ALK is an inclusion criterion in 3 clinical trials for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 3 are open and 0 are closed. Of the trials that contain ALK status and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 3 (2 open) [4].

ALK is an inclusion criterion in 3 clinical trials for lymphoma, of which 1 is open and 2 are closed. Of the trials that contain ALK status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (1 open) [4].

ALK is an inclusion criterion in 3 clinical trials for mantle cell lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ALK status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [4].

ALK is an inclusion criterion in 3 clinical trials for mediastinal large B-cell lymphoma, of which 3 are open and 0 are closed. Of the trials that contain ALK status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [4].

ALK is an inclusion criterion in 3 clinical trials for neuroblastoma, of which 2 are open and 1 is closed. Of the trials that contain ALK status and neuroblastoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [4].

ALK is an inclusion criterion in 3 clinical trials for non-squamous non-small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ALK status and non-squamous non-small cell lung carcinoma as inclusion criteria, 3 are phase 2 (3 open) [4].

ALK is an inclusion criterion in 3 clinical trials for pancreatic carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ALK status and pancreatic carcinoma as inclusion criteria, 3 are phase 2 (2 open) [4].

ALK is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 1 is closed. Of the trials that contain ALK status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (1 open) [4].

ALK is an inclusion criterion in 2 clinical trials for angioimmunoblastic T-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

ALK is an inclusion criterion in 2 clinical trials for Burkitt lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and Burkitt lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

ALK is an inclusion criterion in 2 clinical trials for enteropathy-associated T-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and enteropathy-associated T-cell lymphoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

ALK is an inclusion criterion in 2 clinical trials for follicular lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and follicular lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 2 clinical trials for germinal center B-cell-like diffuse large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and germinal center B-cell-like diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [4].

ALK is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

ALK is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ALK status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [4].

ALK is an inclusion criterion in 2 clinical trials for hepatosplenic T-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and hepatosplenic T-cell lymphoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

ALK is an inclusion criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

ALK is an inclusion criterion in 2 clinical trials for lymphomatoid granulomatosis, of which 2 are open and 0 are closed. Of the trials that contain ALK status and lymphomatoid granulomatosis as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 2 clinical trials for pancreatic adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain ALK status and pancreatic adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) [4].

ALK is an inclusion criterion in 2 clinical trials for peripheral T-cell lymphoma, not otherwise specified, of which 2 are open and 0 are closed. Of the trials that contain ALK status and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

ALK is an inclusion criterion in 2 clinical trials for plasmablastic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and plasmablastic lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

ALK is an inclusion criterion in 2 clinical trials for primary mediastinal B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and primary mediastinal B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open) [4].

ALK is an inclusion criterion in 2 clinical trials for prostate carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and prostate carcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].

ALK is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for anaplastic large cell lymphoma, ALK-negative, of which 1 is open and 0 are closed. Of the trial that contains ALK status and anaplastic large cell lymphoma, ALK-negative as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for atypical Burkitt/Burkitt-like lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and atypical Burkitt/Burkitt-like lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and central nervous system lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for central nervous system neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ALK status and central nervous system neoplasm as inclusion criteria, 1 is early phase 1 (0 open) [4].

ALK is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

ALK is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma activated B-cell type, of which 1 is open and 0 are closed. Of the trial that contains ALK status and diffuse large B-cell lymphoma activated B-cell type as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for EBV-positive mucocutaneous ulcer, of which 1 is open and 0 are closed. Of the trial that contains ALK status and EBV-positive mucocutaneous ulcer as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

ALK is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, of which 1 is open and 0 are closed. Of the trial that contains ALK status and extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue as inclusion criteria, 1 is phase 1 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for follicular T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and follicular T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

ALK is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains ALK status and glioblastoma as inclusion criteria, 1 is early phase 1 (0 open) [4].

ALK is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ALK status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, of which 1 is open and 0 are closed. Of the trial that contains ALK status and indolent T-cell lymphoproliferative disorder of the gastrointestinal tract as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for large B-cell lymphoma with IRF4 rearrangement, of which 1 is open and 0 are closed. Of the trial that contains ALK status and large B-cell lymphoma with IRF4 rearrangement as inclusion criteria, 1 is phase 1 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ALK status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ALK status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ALK status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains ALK status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) [4].

ALK is an inclusion criterion in 1 clinical trial for mature B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and mature B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains ALK status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) [4].

ALK is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for monomorphic epitheliotropic intestinal T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and monomorphic epitheliotropic intestinal T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for mycosis fungoides, of which 1 is open and 0 are closed. Of the trial that contains ALK status and mycosis fungoides as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for nasal type extranodal NK/T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and nasal type extranodal NK/T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for nodal marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and nodal marginal zone lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for nodal peripheral T-cell lymphoma with TFH phenotype, of which 1 is open and 0 are closed. Of the trial that contains ALK status and nodal peripheral T-cell lymphoma with TFH phenotype as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for primary central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and primary central nervous system lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for primary effusion lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and primary effusion lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for Richter syndrome, of which 1 is open and 0 are closed. Of the trial that contains ALK status and Richter syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for sezary syndrome, of which 1 is open and 0 are closed. Of the trial that contains ALK status and sezary syndrome as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for small intestinal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK status and small intestinal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

ALK is an inclusion criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for subcutaneous panniculitis-like T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and subcutaneous panniculitis-like T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for systemic EBV-positive T-cell lymphoma of childhood, of which 1 is open and 0 are closed. Of the trial that contains ALK status and systemic EBV-positive T-cell lymphoma of childhood as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ALK is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

ALK is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

ALK is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].